Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BioNTech SE DRC | BIVA | Healthcare | Biotechnology & Medical Research | MX$464.49B | -61.8x | MX$1,879 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
CRISPR Therapeutics AG | Mexico | Healthcare | Biotechnology & Medical Research | MX$119.17B | -13.1x | 0.18 | MX$1,182.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CRISPR Therapeutics | BIVA | Healthcare | Biotechnology & Medical Research | MX$118.70B | -13.1x | MX$1,182.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Ardelyx | BIVA | Healthcare | Biotechnology & Medical Research | MX$23.46B | -22.3x | MX$122.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Altimmune | BIVA | Healthcare | Biotechnology & Medical Research | MX$6.51B | -3.4x | MX$72.30 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Atossa Therapeutics | BIVA | Healthcare | Biotechnology & Medical Research | MX$2.38B | -4x | MX$17.80 | 6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
FibroGen | Mexico | Healthcare | Biotechnology & Medical Research | MX$876.17M | -0.5x | -0.01 | MX$220 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |